PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3, and it inhibits the PI3K and Ras/ERK pathways, re
Molecular Weight:
407.44
Formula:
C22H22FN5O2
Target:
FLT3,RET
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
